Patient reports are produced minutes after scanning and clinical workflow isn’t significantly affected when using the QyScore.
“QyScore makes a difference for the diagnosis of dementias at an early stage of the disease when it remains a challenge,” said Bruno Dubois, Professor of Neurology at Sorbonne University, and Director of the Memory and Alzheimer’s Disease Institute (IM2A) at Pitié Salpêtrière Hospital in Paris. “The automatic quantification of markers such as brain atrophy, white matter hyperintensities and more, provides highly valuable help to support a timely diagnosis and an efficient monitoring of disease progression.”
Product page: QyScore…
Via: Qynapse
QyScore Analyzes MRIs for Biomarkers of Brain Diseases
Qynapse, a firm headquartered in Paris, France, won FDA clearance for its QyScore software that […]
Original Article: (https://www.medgadget.com/2020/02/qyscore-analyzes-mris-for-biomarkers-of-brain-diseases.html)